Case Studies

Optimising iPSC Manufacturing for Clinical Success

Transformed academic iPSC processes into GMP-ready clinical manufacturing strategies, overcoming significant scalability and regulatory hurdles for innovative cell therapy development.

The Challenge: Overcoming Scalability and Regulatory Hurdle

An innovative cell therapy start-up required a feasibility study to translate its iPSC-based academic process into a GMP-ready clinical manufacturing strategy. Several non-translatable unit operations and an extended culture period posed significant scalability and regulatory hurdles. The client needed a cost-effective, efficient approach to ensure feasibility while maintaining product quality.

Our Approach

eXmoor Pharma worked closely with the client to assess and refine the process for GMP readiness, ensuring seamless technology transfer, process optimisation, and scalability:

The Outcome

Deliverables & Impact

  • Road map for future technology transfer.
  • Assessment and feasibility reports on key unit operations.
  • Comparability studies between research and GMP materials.
  • Next-step process development and CMC strategy.

eXmoor Pharma provided a clear pathway to GMP manufacturing, ensuring process scalability and regulatory alignment. Product quality and yield were optimised, demonstrating the impact of a collaborative approach between the client’s process expertise and eXmoor Pharma’s development capabilities.

Download a copy

Let’s Accelerate Your Therapy Together

Whether you’re in early-stage development or scaling up for commercial production, eXmoor Pharma provides the expertise and flexibility you need. Partner with us to move your therapy forward with confidence.